Jazz Pharmaceuticals (JAZZ) has agreed to acquire Chimerix (CMRX) for $8.55 per share in cash, representing a total consideration of about $935 million, the companies said Wednesday.
The deal consideration reflects a roughly 72% premium based on the company's closing trading price Tuesday.
Upon the successful completion of its tender offer, Jazz will acquire all Chimerix shares not acquired in the tender via a second-step merger, the companies said.
The deal is expected to close in Q2.
Chimerix shares were up 4.6% in recent premarket activity, while Jazz rose 0.1%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。